ع
Vision Ventures detailed in an announcement that it led the pre-seed investment in Madeed to back the development of what the firm described as the Unified Longevity Stack for the Middle East. The platform aims to create an end-to-end biological feedback loop beginning with advanced diagnostics and progressing through clinician-reviewed insights to evidence-based custom-formulated supplements. According to the announcement, Madeed focuses on cardiometabolic health, inflammation control and related areas while avoiding trend-driven offerings in favor of clinically grounded interventions. The approach seeks to close gaps in a currently fragmented longevity market by ensuring each layer communicates effectively with the others.
Dr. Adam Bataineh serves as founder of Madeed and brings experience as a physician who co-founded Span Health, a company acquired by Eight Sleep. The Vision Ventures announcement highlighted Bataineh’s background at the intersection of clinical practice and consumer technology with particular emphasis on solving adherence challenges and improving user experience. His prior work informed the design of a platform that addresses behavioral friction often responsible for the gap between longevity science and real-world results. The founding team targets high-engagement tools that sustain long-term user participation in preventative regimens.
Madeed’s system shifts the emphasis from lagging detection and treatment models to leading optimization and prevention strategies for healthspan. The platform employs low-cost biomarker testing paired with artificial intelligence to synthesize insights before generating personalized daily supplements reviewed by clinicians. In the announcement, Vision Ventures positioned this loop as superior to isolated offerings in diagnostics, supplements or tracking applications that fail to integrate. The startup’s formulations draw exclusively from established clinical evidence rather than popular wellness trends.
Saudi Arabia’s Health Sector Transformation Program under Vision 2030 prioritizes preventive care, enhanced primary health services and disease prevention measures that the government considers more cost-effective than treating advanced illness. A national study published in 2024 found that cardiovascular disease prevalence stands at 1.6 percent among Saudi adults aged 15 and older, rising to 11 percent for those 65 and above, with rates higher among males than females. The World Heart Federation reported 54,791 deaths from cardiovascular disease in Saudi Arabia in 2021 alongside elevated levels of obesity and diabetes that underscore the regional cardiometabolic burden. These conditions align with Madeed’s targeted focus areas and create a receptive environment for precision longevity solutions.
Research and Markets data places the Saudi health check-up market at 175.34 million dollars in 2024 with a projection to reach 219.96 million dollars by 2030 as demand for preventive services expands. Vision Ventures described Madeed as the first platform to fully own the preventative health loop in the MENA region, leveraging Saudi Arabia’s young tech-savvy population and centralized healthcare infrastructure to establish a category-leading position. The announcement noted strong regional fit with Vision 2030 goals that promote quality-of-life improvements and leapfrog opportunities in health technology. Kais Al-Essa, founding partner of Vision Ventures, supported the investment as part of the firm’s strategy to back early-stage innovators addressing local health priorities.
The Vision Ventures announcement stated that the firm believes Madeed will become the default preventative health layer for the Middle East. In the release, Vision Ventures expressed pride in partnering with Dr. Adam Bataineh and the Madeed team at this early stage to support development of a regionally tailored solution. The investment thesis centers on Madeed’s potential to consolidate previously disconnected health layers into a single coherent system that improves outcomes across energy, cognition and metabolic performance. This positions the startup to capture growing demand for evidence-based preventative tools amid rising awareness of long-term healthspan management.
